Pre-clinical evaluation of dual targeting of the GPCRs CaSR and V2R as therapeutic strategy for autosomal dominant polycystic kidney disease.

Interestingly, in this animal model of PKD, R568 appeared to have a more potent effect (51.7% reduction) than lixivaptan (29.5% reduction) relative to control animals, although the difference did not reach statistical significance. 3.2.

also in 111,027 other papers

In the cases where the significance is lost, due to the small sample size, there is a clear trend in the same direction and the effects of treatment are confirmed (Figures S1–S3 ). 3.4.

also in 19,460 other papers

Once again, whereas both lixivaptan and R568 monotherapy showed a trend toward reduction of PKA activity, only the combined lixivaptan and R568 treatment statistically significantly reduced PKA activity (65.3% vs.

also in 53,322 other papers